Clearmind Medicine (Nasdaq: CMND) completes treatment for 18 CMND-100 patients

Rhea-AI Filing Summary

Clearmind Medicine Inc. reported progress in its ongoing FDA-approved Phase I/IIa clinical trial of CMND-100, a proprietary non-hallucinogenic MEAI-based oral drug candidate for Alcohol Use Disorder. The company has successfully completed treatment and follow-up for 18 participants, marking a key early-stage milestone in assessing safety, tolerability, pharmacokinetics, and preliminary efficacy.

Clearmind also completed treatment for four additional participants at its Tel Aviv clinical center, highlighting expanding enrollment and operational strength at its Israeli sites. The trial is being run at leading institutions including Yale University, Johns Hopkins University, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center. Clearmind describes itself as a clinical-stage neuroplastogens pharmaceutical biotech with nineteen patent families and 31 granted patents focused on non-hallucinogenic, second-generation therapeutics for underserved conditions such as Alcohol Use Disorder.

Key Figures

Participants completed: 18 participants Additional participants treated: 4 participants Patent families: 19 patent families +1 more

4 metrics

Participants completed 18 participants Completed treatment and follow-up in Phase I/IIa CMND-100 trial

Additional participants treated 4 participants Newly treated at Tel Aviv clinical center

Patent families 19 patent families Clearmind intellectual property portfolio

Granted patents 31 granted patents Part of Clearmind’s IP portfolio

Key Terms

Phase I/IIa clinical trial, Alcohol Use Disorder, neuroplastogen-derived therapeutics, forward-looking statements, +1 more

5 terms

Phase I/IIa clinical trial medical

"successful completion of treatment and follow-up of 18 participants in its ongoing FDA-approved Phase I/IIa clinical trial evaluating CMND-100"

An early-stage clinical study that combines initial safety testing (Phase I) with a first look at whether a treatment shows signs of working in patients (Phase IIa). Investors watch these trials because they move a therapy from lab research toward proof that it can help people; successful results reduce technical risk and can unlock bigger trials, partnerships, regulatory attention, or increases in a company’s value — like a prototype test that determines whether a product should go into full production.

Alcohol Use Disorder medical

"clinical trial of CMND-100 for Alcohol Use Disorder (AUD)"

A chronic medical condition characterized by an inability to control or stop drinking despite negative effects on health, work, relationships or safety; it ranges from mild to severe based on frequency, loss of control, and withdrawal symptoms. Investors care because its prevalence and treatment options affect markets for pharmaceuticals, medical services and health-related productivity—think of it like a long-running equipment fault in a factory that reduces output and creates demand for repairs and preventive solutions.

neuroplastogen-derived therapeutics medical

"non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems"

Neuroplastogen-derived therapeutics are drugs or biological treatments developed from compounds that promote neuroplasticity — the brain’s ability to rewire and form new connections after injury or in response to learning. For investors, they matter because these therapies target underlying brain repair mechanisms rather than only masking symptoms, offering the potential for durable benefits in conditions like depression, stroke recovery, or neurodegeneration; if effective, they can create large, high-value markets similar to replacing a faulty bridge with a stronger one.

forward-looking statements regulatory

"This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

FDA-approved regulatory

"its ongoing FDA-approved Phase I/IIa clinical trial evaluating CMND-100"

FDA-approved means a medical product, drug, device or treatment has passed the U.S. Food and Drug Administration’s review for safety and effectiveness for a specific use. Think of it like a formal safety and performance seal that allows the product to be marketed for that purpose in the U.S.; for investors, approval reduces regulatory uncertainty, enables sales and reimbursement pathways, and can materially affect a company’s revenue prospects and valuation.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of: March 2026

Commission file number: 001-41557

CLEARMIND MEDICINE INC.

(Translation of registrant’s name into English)

101 – 1220 West 6th Avenue

Vancouver, British Columbia

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒    Form 40-F ☐

CONTENTS

Attached hereto and incorporated herein is the Registrant’s press release issued on March 30, 2026, titled “Clearmind Medicine Announces Successful Completion of Treatment and Follow-up for 18 Participants in its Ongoing Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder”.

1

EXHIBIT INDEX

Exhibit No.
99.1		Press release titled: “Clearmind Medicine Announces Successful Completion of Treatment and Follow-up for 18 Participants in its Ongoing Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder”

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Clearmind Medicine, Inc.
	(Registrant)
Date: March 30, 2026	By:	/s/ Adi Zuloff-Shani
	Name:	Adi Zuloff-Shani
	Title:	Chief Executive Officer

3

Exhibit 99.1

 

Clearmind Medicine Announces Successful Completion of Treatment and Follow-up for 18 Participants in its Ongoing Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder

Company completed treatment in four additional participate at its Israel clinical site

Vancouver, Canada, March 30, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the successful completion of treatment and follow-up of 18 participants in its ongoing FDA-approved Phase I/IIa clinical trial evaluating CMND-100, the Company’s proprietary non-hallucinogenic MEAI-based oral drug candidate, for the treatment of Alcohol Use Disorder (AUD).

This milestone reflects continued positive progress and strong momentum in the multinational, multicenter study, which is designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100 in patients with moderate to severe AUD.

The Company also wishes to announce that four additional participants have been successfully treated at the clinical center in Tel Aviv, further expanding enrollment and demonstrating the operational strength of the Israeli sites in the trial.

“We are very encouraged by the successful completion of treatment and follow-up for these 18 participants, alongside the rapid addition of four more patients at our Tel Aviv center,” said Dr. Adi Zuloff-Shani, Chief Executive Officer of Clearmind Medicine. “This steady progress across our sites underscores the favorable safety and tolerability profile of CMND-100 and brings us closer to potentially delivering a much-needed innovative therapy for Alcohol Use Disorder.”

The Phase I/IIa clinical trial is being conducted at leading institutions, including Yale University, Johns Hopkins University, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center.

About Clearmind Medicine Inc.

Clearmind is a clinical-stage neuroplastogens pharmaceutical biotech company focused on the discovery and development of non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements.

The Company’s intellectual portfolio currently consists of nineteen patent families, including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

Shares of Clearmind are listed for trading on Nasdaq under the symbol “CMND.”

For further information, visit: https://www.clearmindmedicine.com or contact:

Investor Relations

invest@clearmindmedicine.com

www.Clearmindmedicine.com

Forward-Looking Statements:

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the timing and progress of its clinical trials and potentially delivering a much-needed innovative therapy for Alcohol Use Disorder. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.

FAQ

What clinical milestone did Clearmind Medicine (CMND) announce?

Clearmind Medicine announced completion of treatment and follow-up for 18 participants in its FDA-approved Phase I/IIa trial of CMND-100 for Alcohol Use Disorder, marking a key early-stage milestone in evaluating safety, tolerability, pharmacokinetics, and preliminary efficacy.

What is CMND-100 in Clearmind Medicine’s Phase I/IIa trial?

CMND-100 is Clearmind Medicine’s proprietary, non-hallucinogenic, MEAI-based oral drug candidate for treating Alcohol Use Disorder. The ongoing Phase I/IIa trial is designed to evaluate its safety, tolerability, pharmacokinetics, and preliminary efficacy in patients with moderate to severe Alcohol Use Disorder.

How many participants have been treated in Clearmind’s CMND-100 study?

Clearmind has completed treatment and follow-up for 18 participants in its Phase I/IIa CMND-100 trial and reports four additional participants treated at its Tel Aviv clinical center, indicating growing enrollment and operational activity across its multinational, multicenter study sites.

Which institutions are involved in Clearmind Medicine’s CMND-100 trial?

The CMND-100 Phase I/IIa trial is being conducted at leading institutions: Yale University, Johns Hopkins University, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center. These centers support the multinational, multicenter design focused on Alcohol Use Disorder patients with moderate to severe disease.

What therapeutic focus does Clearmind Medicine (CMND) have?

Clearmind Medicine is a clinical-stage neuroplastogens pharmaceutical biotech developing non-hallucinogenic, second-generation, neuroplastogen-derived therapeutics. It targets widespread, underserved health problems, including Alcohol Use Disorder, and holds nineteen patent families with 31 granted patents supporting its psychedelic-based compound portfolio.

Where are Clearmind Medicine shares listed and under what symbol?

Clearmind Medicine shares are listed on Nasdaq under the symbol CMND. The company is a clinical-stage biotech focused on non-hallucinogenic neuroplastogen-derived therapeutics and is advancing CMND-100 for Alcohol Use Disorder through an FDA-approved Phase I/IIa clinical trial.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 PRESS RELEASE TITLED: "CLEARMIND MEDICINE ANNOUNCES SUCCESSFUL COMPLETION OF TRE 10.1 KB